Previously, SHISA3 has been described as an antagonist of Wnt/β-catenin pathway in lung cancer by reducing Wnt receptors, accelerating β-catenin degradation and ultimately suppressing Wnt-mediated gene expression [17]. The gene discussed is SHISA3; the disease is lung cancer.